BR112022012283A2 - Combinações - Google Patents
CombinaçõesInfo
- Publication number
- BR112022012283A2 BR112022012283A2 BR112022012283A BR112022012283A BR112022012283A2 BR 112022012283 A2 BR112022012283 A2 BR 112022012283A2 BR 112022012283 A BR112022012283 A BR 112022012283A BR 112022012283 A BR112022012283 A BR 112022012283A BR 112022012283 A2 BR112022012283 A2 BR 112022012283A2
- Authority
- BR
- Brazil
- Prior art keywords
- combinations
- disease
- compounds
- condition
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
- Glass Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952032P | 2019-12-20 | 2019-12-20 | |
| PCT/US2020/065410 WO2021127045A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012283A2 true BR112022012283A2 (pt) | 2022-08-30 |
Family
ID=76478077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012283A BR112022012283A2 (pt) | 2019-12-20 | 2020-12-16 | Combinações |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230054854A1 (enExample) |
| EP (1) | EP4069242A4 (enExample) |
| JP (1) | JP7750526B2 (enExample) |
| KR (1) | KR20220119420A (enExample) |
| CN (2) | CN121102230A (enExample) |
| AU (1) | AU2020404996A1 (enExample) |
| BR (1) | BR112022012283A2 (enExample) |
| CA (1) | CA3165474A1 (enExample) |
| IL (1) | IL294094A (enExample) |
| MX (1) | MX2022007623A (enExample) |
| TW (1) | TWI875898B (enExample) |
| WO (1) | WO2021127045A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4566612A3 (en) | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2023147297A2 (en) * | 2022-01-25 | 2023-08-03 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102124715B1 (ko) * | 2015-11-03 | 2020-06-18 | 제넨테크, 인크. | 암의 치료를 위한 bcl-2 억제제 및 mek 억제제의 조합물 |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| KR20200108301A (ko) * | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| WO2019165204A1 (en) * | 2018-02-23 | 2019-08-29 | Newave Pharmaceutical Inc. | 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase |
| US12220415B2 (en) * | 2018-02-28 | 2025-02-11 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
-
2020
- 2020-12-16 AU AU2020404996A patent/AU2020404996A1/en active Pending
- 2020-12-16 KR KR1020227024701A patent/KR20220119420A/ko active Pending
- 2020-12-16 IL IL294094A patent/IL294094A/en unknown
- 2020-12-16 BR BR112022012283A patent/BR112022012283A2/pt unknown
- 2020-12-16 CN CN202511346658.2A patent/CN121102230A/zh active Pending
- 2020-12-16 US US17/757,530 patent/US20230054854A1/en active Pending
- 2020-12-16 WO PCT/US2020/065410 patent/WO2021127045A1/en not_active Ceased
- 2020-12-16 JP JP2022538232A patent/JP7750526B2/ja active Active
- 2020-12-16 MX MX2022007623A patent/MX2022007623A/es unknown
- 2020-12-16 CA CA3165474A patent/CA3165474A1/en active Pending
- 2020-12-16 EP EP20904098.9A patent/EP4069242A4/en active Pending
- 2020-12-16 CN CN202080095323.7A patent/CN115135325B/zh active Active
- 2020-12-18 TW TW109145167A patent/TWI875898B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202135819A (zh) | 2021-10-01 |
| CN115135325A (zh) | 2022-09-30 |
| WO2021127045A1 (en) | 2021-06-24 |
| CN115135325B (zh) | 2026-04-03 |
| AU2020404996A1 (en) | 2022-07-14 |
| EP4069242A4 (en) | 2024-01-10 |
| CA3165474A1 (en) | 2021-06-24 |
| CN121102230A (zh) | 2025-12-12 |
| NZ790037A (en) | 2025-08-29 |
| US20230054854A1 (en) | 2023-02-23 |
| JP2023508332A (ja) | 2023-03-02 |
| EP4069242A1 (en) | 2022-10-12 |
| MX2022007623A (es) | 2022-09-23 |
| IL294094A (en) | 2022-08-01 |
| KR20220119420A (ko) | 2022-08-29 |
| TWI875898B (zh) | 2025-03-11 |
| JP7750526B2 (ja) | 2025-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022012283A2 (pt) | Combinações | |
| BR112022012280A2 (pt) | Combinações | |
| BR112022012281A2 (pt) | Combinações | |
| BR112022012278A2 (pt) | Combinações | |
| BR112018000808A2 (pt) | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase | |
| CL2020001797A1 (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas. | |
| WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
| EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| BR112022012266A2 (pt) | Combinações | |
| BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
| BR112016030541A2 (pt) | métodos para o tratamento de infecções fúngicas | |
| MX2022005256A (es) | Inhibidores de cd73. | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| CY1124907T1 (el) | Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| BR112021025645A2 (pt) | Degradação de proteína alvo de parp14 para uso em terapia | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| MX382765B (es) | Tratamiento para la colangitis biliar primaria. | |
| BR112019000453A2 (pt) | combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| CR20220071A (es) | Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |